Chlamydia pneumoniae and the lung

European Respiratory Journal

Volumn 16, Issue 5, 2000, Pages 1001-1007

  Hammerschlag, M R ^a  

^a NONE   (United States)

Author keywords

Asthma; Chlamydia pneumoniae; Community acquired pneumonia; Pulmonary infection

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; SPARFLOXACIN; SULFAMETHOXAZOLE; TELITHROMYCIN; TROVAFLOXACIN;

ANTIBIOTIC THERAPY; ARTICLE; ATHEROSCLEROSIS; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; HUMAN; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SERODIAGNOSIS;

ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; LUNG DISEASES; POLYMERASE CHAIN REACTION; PREVALENCE; SEROLOGIC TESTS;

EID: 0034526123     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00.16510010     Document Type: Article

References (56)

1. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR
2. Epizootiology of chlamydia infections in two free-range koala populations
3. Influence of temperature and relative humidity on the survival of Chlamydia pneumoniae in aerosols
4. Transmission of Chlamydia pneumoniae
5. Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR
6. Spread of subclinical Chlamydia pneumoniae infection in a closed community
7. An epidemic of infections due to Chlamydia pneumoniae in military conscripts
8. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes
9. Transmission of Chlamydia pneumoniae in young children in a Japanese family
10. Community-acquired pneumonia due to atypical organisms in adults: Diagnosis and treatment
11. Incidence of community-acquired pneumonia requiring hospitalization
12. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
13. Atypical pneumonia in the Nordic countries: Aetiology and clinical results of a trial comparing fleroxacin and doxycycline
14. Implications for macrolide treatment in community-acquired pneumonia
15. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: Comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate
16. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children
17. Chlamydia pneumoniae - Induced ciliostasis in ciliated bronchial epithelial cells
18. Persistent infection with Chlamydia pneumoniae following acute respiratory illness
19. Molecular evaluation of serial isolates from patients with persistent Chlamydia pneumoniae infections
20. Endemic prevalence of Chlamydia pneumoniae in subjectively healthy persons
21. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: Assessment by polymerase chain reaction-enzyme immunoassay and culture
22. The association of Chlamydia pneumoniae infection and reactive airway disease in children
23. Chlamydia pneumoniae in acute otitis media
24. Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease
25. Chlamydia pneumoniae with pleural effusion: Diagnosis by culture
26. Case report: Acute postoperative respiratory failure caused by Chlamydia pneumoniae and diagnosed by bronchoalveolar lavage
27. Experimental infection with Chlamydia pneumoniae in nonhuman primates
28. Pathologic manifestation of chlamydia infection
29. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis
30. Antibiotics in acute bronchitis: A meta-analysis
31. Pathogenesis of lower respiratory tract infections due to chlamydia, mycoplasma, legionella and viruses
32. Chlamydia pneumoniae, asthma and COPD: What is the evidence?
33. Chronic Chlamydia pneumoniae infection and asthma exacerbations in children
34. Effect of hydrocortisone succinate on growth of Chlamydia pneumoniae in vitro
35. Detection of Anti-Chlamydia pneumoniae IgE in children with reactive airway disease
36. Chlamydia pneumoniae and asthma
37. Chlamydia pneumoniae and possible relationship to asthma: Serum immunoglobulins and histamine release in patients and controls
38. Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD
39. Chlamydia pneumoniae infection in acute exacerbations of COPD
40. Use of Hep-2 cells for improved isolation and passage of Chlamydia pneumoniae
41. Molecular diagnosis of Chlamydia pneumoniae infection
42. Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients
43. Chlamydia serology: Inter-laboratory variation in micro-immunofluorescence results
44. Antibody response to Chlamydia pneumoniae infection in children with respiratory illness
45. Genome sequences of Chlamydia Trachomatis MoPn and Chlamydia Pneumoniae AR39
46. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae
47. Activity of quinolones against Chlamydia pneumoniae
48. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections
49. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization
50. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis
51. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia
52. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia
53. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae
54. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae
55. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia pneumoniae and characterization of quinolone-resistant mutants obtained in vitro
56. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model